A detailed history of Column Capital Advisors, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Column Capital Advisors, LLC holds 2 shares of BIIB stock, worth $451. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 11 81.82%
Holding current value
$451
Previous $3,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 03, 2023

SELL
$253.3 - $285.89 $2,279 - $2,573
-9 Reduced 81.82%
2 $0
Q1 2022

May 03, 2022

SELL
$193.77 - $244.14 $6,781 - $8,544
-35 Reduced 76.09%
11 $2,000
Q3 2021

Nov 10, 2021

SELL
$282.99 - $369.05 $282 - $369
-1 Reduced 2.13%
46 $13,000
Q2 2021

Aug 05, 2021

SELL
$259.0 - $414.71 $45,325 - $72,574
-175 Reduced 78.83%
47 $16,000
Q2 2020

Aug 12, 2020

SELL
$258.66 - $342.55 $517 - $685
-2 Reduced 0.89%
222 $59,000
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $49,293 - $68,111
224 New
224 $66,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $32.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Column Capital Advisors, LLC Portfolio

Follow Column Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Column Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Column Capital Advisors, LLC with notifications on news.